SCHEMBL1198969

SCHEMBL1198969

CCOC(=O)c1cnn(Cc2nc(-c3cccc(C(C)(F)F)c3)cs2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 4/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
GAA P10253 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
TDP1 Q9NUW8 1/20 0.43
KCNH2 Q12809 2/20 0.41
GRM2 Q14416 1/20 0.40
ITGB2 P05107 2/20 0.40
ICAM1 P05362 2/20 0.40
ITGAL P20701 2/20 0.40
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198067 0.95 KDM4E (0.49) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1198746 0.88 ALDH1A1 (0.50) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL1198553 0.88 ALDH1A1 (0.44) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL12890119 0.88 ALDH1A1 (0.44) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1199202 0.88 KDM4E (0.46) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1198866 0.87 KDM4E (0.55) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1198711 0.87 L3MBTL1 (0.49) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL12875680 0.87 L3MBTL1 (0.44) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1198899 0.86 KDM4E (0.44) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1198716 0.86 SMN1; SMN2 (0.46) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KDM4E 1877/4885ALDH1A1 1037/4885HPGD 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.